Slaughter and May advised GlaxoSmithKline plc (“GSK”) on the sale of its remaining 6.2% stake in Aspen Pharmacare Holdings Ltd which was announced on 28 September 2016. The disposal was effected by way of an accelerated bookbuilt offering and raised gross proceeds equivalent to £477 million.

GSK’s internal legal team was led by Antony Braithwaite and we worked as an integrated team with Cleary Gottlieb Steen & Hamilton LLP advising on US law and Bowman Gilfillan Inc. advising on South African law.
Contacts

Corporate and Commercial: David Johnson (partner), Chris McGaffin (partner), David Hughes (associate)

Cleary Gottlieb Steen & Hamilton: Sebastian R. Sperber (partner), Laura K. Palmer (associate)

Bowman Gilfillan: Ezra Davids (partner), Ryan Wessels (partner)